Muniesa, C., Gallardo, F., García‐Doval, I., Estrach, M. T., Combalia, A., Morillo‐Andújar, M., De la Cruz‐Vicente, F., Machan, S., Moya‐Martínez, C., Rovira, R., Sanchez‐Gonzalez, B., Acebo, E., Amutio, E., Peñate, Y., Losada‐Castillo, M. d. C., García‐Muret, M. P., Iznardo, H., Román‐Curto, C., Cañueto, J., Fernández‐de‐Misa, R., Flórez, Á., Izu, R. M., Torres‐Navarro, I., Zayas, A., Pérez‐Paredes, G., Blanes, M., Yanguas, J. I., Pérez‐Ferriols, A., Callejas‐Charavia, M., Ortiz‐Romero, P. L., Pérez‐Gil, A., Prieto‐Torres, L., González‐Barca, E., & Servitje, O. (2023). brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the European Academy of Dermatology and Venereology, 37, 57–64. http://access.bl.uk/ark:/81055/vdc_100172532033.0x000039